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Abstract 
Current evidence demonstrates that the stomach-derived hormone ghrelin, a potent growth hormone (GH) 
secretagogue, promotes feeding through a mechanism involving the short-term activation of hypothalamic 
AMP-activated protein kinase (AMPK), which in turn results in decreased hypothalamic levels of malonyl-
CoA and increased carnitine palmitoyltransferase 1 (CPT1) activity. Despite this evidence, no data have been 
reported about the effect of chronic, central ghrelin administration on hypothalamic fatty acid metabolism. In 
the present study, we examined the differences in hypothalamic fatty acid metabolism in the presence and 
absence of GH, by using a model for the study of GH-deficiency, namely the spontaneous dwarf rat and the 
effect of long-term central ghrelin treatment and starvation on hypothalamic fatty acid metabolism in this 
animal model. Our data showed that GH-deficiency induces reductions in both de novo lipogenesis and β-
oxidation pathways in the hypothalamus. Thus, dwarf rats display reductions in fatty acid synthase (FAS) 
mRNA expression both in the ventromedial nucleus of the hypothalamus (VMH) and whole hypothalamus, as 
well as in FAS protein and activity. CPT1 activity was also reduced. In addition, in the present study, we 
show that chronic ghrelin treatment does not promote AMPK-induced changes in the overall fluxes of 
hypothalamic fatty acid metabolism in normal rats and that this effect is independent of GH status. By 
contrast, we demonstrated that both chronic ghrelin and fasting decreased FAS mRNA expression in the 
VMH of normal rats but not dwarf rats, suggesting GH status dependency. Overall, these results suggest that 
ghrelin plays a dual time-dependent role in modulating hypothalamic lipid metabolism. Understanding the 
molecular mechanism underlying the interplay between GH and ghrelin on hypothalamic lipid metabolism 
will allow new strategies for the design and development of suitable drugs for the treatment of GH-
deficiency, obesity and its comorbidities. 
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Data gleaned in the last decade have demonstrated that hypothalamic fatty acid metabolism 
plays a major role in the modulation of energy balance. Anatomical data show that central 
enzymes involved in fatty acid metabolism, such as acetyl-CoA carboxylase (ACC), fatty acid 
synthase (FAS), malonyl-CoA decarboxylase (MCD), carnitine palmitoyltransferase 1 (CPT1), 
AMP-activated protein kinase (AMPK) and Ca
2+
/calmodulin-dependent protein kinase kinase 2 
(an upstream kinase of AMPK), are expressed at particularly high levels in several hypothalamic 
nuclei modulating energy balance, such as the arcuate (ARC), dorsomedial (DMH), 
paraventricular (PVH) and ventromedial (VMH) nuclei (1,2). Pharmacologic and genetic evidence 
demonstrate that altered levels and activity of these enzymes can modulate feeding (2–5). 
Importantly, physiological data have also shown that regulation of hypothalamic fatty acid 
metabolism is a bona fide component of the energy homeostasis system. Whereas fasting activates 
hypothalamic AMPK and inhibits ACC and FAS, refeeding induces opposite changes (1,2). 
Moreover, hypothalamic fatty acid metabolism integrates peripheral signals, such as hormones 
[i.e. leptin, ghrelin, insulin, glucagon-like peptide-1 (GLP-1), cannabinoids, glucocorticoids and 
adiponectin] (1,6–10) and nutrients/metabolites (i.e. glucose, α-lipoic acid and citrate) (11,12), 
with the hypothalamic networks modulating energy balance, in particular with the ARC 
populations expressing agouti-related protein/neuropeptide Y (AgRP/NPY) and cocaine- and 
amphetamine-regulated transcript/pro-opiomelanocortin (CART/POMC). 
 
Among the different hormones modulating hypothalamic fatty acid metabolism, much attention 
has been focused on ghrelin, a secreted 28-residue peptide hormone from the stomach. Ghrelin is 
the endogenous ligand that binds to the growth hormone (GH) secretagogue receptor (GHS-R) 
(13), which in the hypothalamus, is expressed in NPY/AGRP-, POMC-, and growth hormone 
releasing hormone-containing neurones (14,15). Plasma levels of ghrelin are regulated by food 
intake, rising during fasting and immediately prior to meals and falling after food intake (16,17). 
Compelling evidence has demonstrated that central and peripheral acute ghrelin administration 
activates AMPK (1,6,10,18). As a direct result of this effect, ACC activity is reduced, which 
results in decreased hypothalamic levels of malonyl-CoA and increased CPT1 activity (1), leading 
to changes in hypothalamic mitochondrial oxidation and production of reactive oxygen species, 
which are dependent on uncoupling protein 2 (10). This activation of the mitochondrial oxidative 
machinery is critical for ghrelin-induced activation of NPY/AgRP neurones and for ghrelin-
induced food intake; indeed, pharmacological or genetic inhibition of AMPK or CPT1 blunts 
ghrelin-induced food intake (1,10). 
 
Despite this evidence linking hypothalamic fatty acid metabolism with ghrelin in acute 
settings, no data have been reported about the effect of chronic central ghrelin administration on 
the hypothalamic AMPK-malonyl-CPT1 axis. Current evidence has demonstrated that central 
chronic treatment with ghrelin increases adiposity by stimulation of the lipogenic program in the 
white adipose tissue (WAT) via the sympathetic nervous system, in a food intake-independent 
fashion (19,20) and diminishes beta-oxidation in liver in a GH-dependent fashion (20). In 
particular, central ghrelin administration elicited the mRNA expression of several fat storage-
promoting enzymes in WAT, such as lipoprotein lipase, ACC, FAS and stearoyl-CoA desaturase-1 
(SCD-1) (19,20). Whether a similar mechanism takes place in the hypothalamus is currently 
unresolved. Thus, the present study first aimed to investigate the effect of chronic central ghrelin 
administration on hypothalamic fatty acid metabolism. 
 
Fasting is a natural situation characterised in rats by high levels of ghrelin (17) and low levels 
of GH (21). In addition, ghrelin is a potent GH secretagogue in both rodents and humans (22). 
Moreover, it is known that the GHS-R expression is affected by GH status (23) and that GH 
receptor deficiency results in blunted ghrelin-induced feeding response in mice (24). For these 
reasons, we also explored the GH-dependency of both fasting and ghrelin-induced effect on 
hypothalamic fatty acid metabolism by using the spontaneous dwarf rat (SDR), a classical model 
for the study of GH-deficiency (25). 
  
Materials and methods 
Animals 
We utilised two male rat models, wild-type (controls) and GH-deficient (dwarf) Lewis rats 
(HsdOla:dw-4, 2–3 months old; body weight: 365 ± 4 g and 222 ± 5 g, respectively, Harlan, 
Bicester, UK). Rats were housed in a temperature controlled room, under a 12 : 12 h light/dark 
cycle (lights on 08.00 h). The animals were sacrificed at 16.00 h. All experiments and procedures 
involved in the present study were reviewed and approved by the Ethics Committee of the USC, in 
accordance with EU normative for the use of experimental animals. 
Study of hypothalamic fatty acid metabolism in wild-type and GH-deficient Lewis rats 
To study the possible differences in hypothalamic fatty acid metabolism and neuropeptides 
levels as a result of GH deficiency, we sacrificed wild-type and GH-deficient Lewis rats without 
any kind of treatment. We used eight rats per group. 
Fasting experiments 
To study hypothalamic metabolism in a natural situation with high levels of ghrelin, normal 
and GH-deficient rats were fasted for 48 h. Groups comprised six to eight rats. 
Infusion of ghrelin into lateral ventricle in wild-type and GH-deficient Lewis rats 
To assess the chronic effects of i.c.v. ghrelin treatment on hypothalamic fatty acid metabolism 
in presence or absence of GH, normal and GH-deficient rats were infused into lateral ventricle 
with saline as vehicle (controls) or acyl-ghrelin (Bachem catalogue number H-4864; Bachem AG, 
Bubendorf, Switzerland) for 8 days. Chronic i.c.v. cannulae were implanted under 
ketamine/xylazine anaesthesia as previously described (1,20,26). The correct location of the 
cannulae in the lateral ventricle was confirmed by methylene blue staining. Animals were 
individually caged and allowed to recover for 1 week before the experiment. During the 
postoperative recovery period, the rats were handled regularly under nonstressful conditions. A 
catheter tube was connected from the brain infusion cannulae to an osmotic mini-pump flow 
moderator (model 2001D or 2ML2; Alzet Corp., Palo Alto, CA, USA). A subcutaneous pocket on 
the dorsal surface of the animal was created using blunt dissection, and the osmotic mini-pump 
was inserted. The incision was closed with sutures, and the rats were kept warm until fully 
recovered. The rats were then infused with either vehicle alone (saline) or vehicle containing acyl-
ghrelin; the pumps released the solutions at a rate of 1 μl/h and 20 μg ghrelin/day. Animals were 
treated for 8 days. Groups comprised six to eight rats. 
Tissue dissection 
Rats were killed by cervical dislocation and trunk blood was extracted. The hypothalamus [for 
real-time polymerase chain reaction (PCR)] or the whole brain (for studies of in situ hybridisation) 
were dissected and stored at −80 °C until further processing and analysis. The hypothalamus was 
defined by the posterior margin of the optic chiasm and the anterior margin of the mammillary 
bodies to the depth of approximately 2 mm. Fresh hypothalami were homogenised with a motor 
pestle in 500 μl ice-cold buffer: 20 mm Tris-HCl (pH 7.4), 250 mm sucrose, 1 mm 
ethylenediaminetetraacetic acid, 1 mm dithiothreitol, 100 mm NaF and protease inhibitor cocktail 
(Roche, Indianapolis, IN, USA). Subsequently, homogenates were centrifuged for 10 min at 
1000 g and the supernatant was extracted and part used for studies of CPT1 activity. The 
remainder was frozen at −80 °C for further analysis by western blotting and assay of the enzymatic 
activities of FAS, glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate 
dehydrogenase (6PGDH). 
Real-time quantitative PCR 
Expression of mRNA levels of ACCα, CPT1M (muscle type isoform) CPT1L (liver type 
isoform), CPT1C (brain type isoform), FAS, SCD-1 and sterol-regulatory-element-binding 
protein-1c (SREBP1c) in hypothalamus were studied using real-time PCR (TaqMan
®
; Applied 
Biosystems, Foster City, CA, USA) with specific primers and probes (Table 1) as previously 
described (1,26). All reactions were carried out using the cycling parameters: 50 °C for 2 min, 
95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. For data analysis, 
the input value of the target gene was standardised to the 18S value for each sample. Data are 
expressed in comparison with the average value for the control group. Groups comprised six rats. 
Table 1.   Primer Sequences Used for Real Time Reverse Transcriptase-Polymerase Chain Reaction. 
Gene Accesion number     
    
ACCα NM_022193 Forward 5′-TGGGCGGGATGGTCTCTTT-3′ 
Reverse 5′-AGTCGCAGAAGCAGCCCATT-3′ 
Probe FAM-5′-ACCTTTGAAGATTTCGTCAGGATCTTTGATGA-3′-TAMRA 
CPT1C XM_001078512.1 Forward 5′-CGCTCCTGGAAAAGGAATCTC-3′ 
Reverse 5′-CGGGACCACACCAGCAA-3′ 
Probe FAM-5′-CGTGTCTGGAATGACTTT-3′-TAMRA 
CPT1L NM_031559 Forward 5′-ATGACGGCTATGGTGTCTCC -3′ 
Reverse 5′-TCATGGCTTGTCTCAAGTGC -3′ 
Probe FAM-5′-TGAGACAGACTCAGACCGCT-3′-TAMRA 
CPT1M NM_013200.1 Forward Commercial primers provided by Applied Biosystems (Ref. Rn01407782_g1) 
FAS NM_017332 Forward 5′-GACATTTCATCAGGCCACC-3′ 
Reverse 5′-CCTCTAGCAGCCGCACCTC-3′ 
Probe FAM-5′-CTGCCCAGGACAGGAACCG-3′-TAMRA 
SCD-1 NM_139192.2 Forward 5′-TGCCAGAGGGAATAGGGAAA-3′ 
Reverse 5′- CTCTCCCATCCTTACTTACAAACCA-3′ 
Probe FAM-5′-TCACCTTGAGAGAAGAATTAGCACGCACGG-3′-TAMRA 
SREBP1c XM_213329 Forward 5′-CTCATCAACAACCAAGACAG-3′ 
Reverse 5′-CCTGTCTCACCCCCAGCAT-3′ 
Probe FAM-5′-CCCTGGCCTATTTGATGCC-3′-TAMRA 
18S V01270.1 Forward 5′-CGGCTACCACATCCAAGGAA-3′ 
Reverse 5′-GCTGGAATTACCGCGGCT-3′ 
Probe FAM-5′-GACGGCAAGTCTGGTGCCAGCA-3′-TAMRA 
    
 
 
 
 
  
Western blotting 
Total protein lysates from hypothalamus (40 μg) were subjected to sodium dodecyl sulphate-
polyacrylamide gel electrophoresis, electrotransferred on a polyvinylidene difluoride membrane 
and probed with the indicated antibodies: ACC, phosphoACC-Ser79 (pACC), AMPKα1 and 
AMPKα2 (Upstate, Lake Placid, NY, USA); phospho-AMPKα-Thr172 (pAMPKα) (Cell 
Signaling, Danvers, MA, USA); β-actin (Abcam, Cambridge, UK); CPT1M, FAS, SREBP1c and 
CPT1L (Santa Cruz Biotechnology, Santa Cruz, CA, USA); CPT1C (Proteintech Europe, 
Manchester, UK), as previously described (1). Protein detection was performed using horseradish 
peroxidase-conjugated secondary antibodies and chemiluminescence (Amersham Biosciences, 
Little Chalfont, UK). Groups comprised six to eight rats and the protein levels were normalised to 
β-actin for each sample. 
In situ hybridisation 
Coronal hypothalamic sections (16 μm) from frozen brain were cut on a cryostat, mounted on 
slides and immediately stored at −80 °C until hybridisation. Specific oligos for AgRP, FAS and 
NPY detection were used (Table 2) as previously described (1). These probes were 3′-end labelled 
with 35S-αdATP using terminal deoxynucleotidyl transferase (Amersham Biosciences). In situ 
hybridisations were performed as previously described (1). The slides from all experimental 
groups were exposed to the same autoradiographic film. All sections were scanned and the specific 
hybridisation signal was quantified by densitometry using a digital imaging system (ImageJ, 
version 1.33; NIH, Bethesda, MD, USA). The optical density of the hybridisation signal was 
determined and subsequently corrected by the optical density of its adjacent background value. 
Groups comprised seven rats. 
Table 2.   Antisense Oligonucleotides for In Situ Hybridisation Analysis. 
Gene Accesion number Sequence 
   
AgRP AF206017 5′-CGACGCGGAGAACGAGACTCGCGGTTCTGTGGATCTAGCACCTCTGCC-3′ 
FAS NM_017332 5′-GGGTCCATTGTGTGTGCCTGCTTGGGGTG-3′ 
NPY M20373 5′-AGATGAGATGTGGGGGGAAACTAGGAAAAGTCAGGAGAGCAAGTTTCATT-3′ 
   
 
Enzyme assays 
Enzyme activities of FAS, CPT1, G6PDH and 6PGDH were determined by spectrophotometry 
using a microplate reader (Tecan, Sunrise, Switzerland). The reactions were started by the addition 
of homogenates (30 μl) and substrates (20 μl, omitted in controls) to the reaction mixture (final 
volume 0.25 ml), and allowing the reactions to proceed at 37 °C for pre-established times (5–
15 min). FAS (27) G6PDH, 6PGDH (28) and CPT1 (1, 26) activities were measured using 
methods previously described. CPT1 activity was assayed in fresh tissue preserving mitochondrial 
integrity so as to avoid contamination with CPT2. Groups comprised six to eight rats. 
  
Statistical analysis 
Data are expressed as percentage of wild-type rats, fed rats or those infused with saline (control 
groups). Data are expressed as the mean ± SEM. Statistic significance was determined by 
Student’s t-test. P < 0.05 was considered statistically significant. 
Results 
Effects of GH deficiency on hypothalamic lipid metabolism and neuropeptide levels 
Gene expression, protein and activity levels of key enzymes involved in the regulation of lipid 
metabolism in hypothalamus of untreated wild-type and GH-deficient Lewis rats are shown in 
Fig. 1(a–g). GH deficiency markedly diminished mRNA levels of FAS and CPT1C (Fig. 1a). 
Protein levels of pACCα, FAS and SREBP1c were lower in dwarf rats compared to normal Lewis 
rats and both phosphorylated and total protein levels of AMPK were higher in GH deficient Lewis 
rats compared to controls (Fig. 1b, c). In dwarf rats, CPT1 and FAS activities were lower compared 
to controls (Fig. 1d). Similar results were observed for G6PDH activity. Because recent data have 
shown that FAS is specifically modulated in the VMH (1, 26), we examined the effect of GH-
deficiency at this level. The data obtained showed that FAS mRNA levels in VMH were markedly 
lower in dwarf rats compared to wild-type Lewis rats (Fig. 1e, g). Similar data were obtained when 
studying the mRNA levels of AgRP and NPY in the ARC (Fig. 1f, g). 
  
 
 
 
Figure 1.  Hypothalamic mRNA (a), protein (b, c) and activity levels (d) of lipid metabolism-related enzymes in wild-type 
and growth hormone-deficient Lewis rats. Fatty acid synthase (FAS) mRNA levels in ventromedial nucleus of the 
hypothalamus (VMH) (e, g) and neuropeptide Y (NPY) and agouti-related protein (AgRP) mRNA levels (g) in the arcuate 
nucleus (ARC) (f, g). Values are expressed as the mean ± SEM. *, **, ***P < 0.05, 0.01 and 0.001, respectively, versus 
wild-type Lewis.  
Effects of fasting on hypothalamic lipid metabolism in wild-type and GH-deficient Lewis rats 
Next, we studied the fasting-induced effect in the hypothalamus of wild-type and GH-deficient 
Lewis rats; the results obtained are shown in Figs 2(a–f) and 3(a–f). In general, fasting exerted a 
marked effect on fatty acid metabolism in normal rats, which was not as clearly evident in GH-
deficient dwarf rats. Food deprivation diminished protein levels of FAS and SREBP1c and 
increased the levels of pAMPKα, AMPKα2, CPT1L and CPT1M in wild-type Lewis rats 
(Fig. 2a, b) but not in dwarf rats (Fig. 3a, b). However, FAS, CPT1 and 6PGDH activities 
significantly diminished after fasting in both models of rats (Figs 2c and 3c). Finally, fasting 
decreased FAS mRNA levels in VMH only in wild-type rats (Figs 2d–f and 3d–f); inversely, 
fasting enhanced NPY and AgRP mRNA levels in ARC in both strains of rat (Figs 2e, f and 3e, f). 
  
 
 
 
Figure 2.  Hypothalamic protein (a, b) and activity levels (c) of lipid metabolism-related enzymes and fatty acid synthase 
(FAS) mRNA levels in ventromedial nucleus of the hypothalamus (VMH) (d, f), neuropeptide Y (NPY) and agouti-related 
protein (AgRP) mRNA levels in the arcuate nucleus (ARC) (e, f) and plasma ghrelin levels (G) in fed and fasted wild-type 
Lewis rats. Values are expressed as the mean ± SEM. *, **, ***P < 0.05, 0.01 and 0.001, respectively, versus fed. 
  
 
 
 
Figure 3.  Hypothalamic protein (a, b) and activity levels (c) of lipid metabolism-related enzymes and fatty acid synthase 
(FAS) mRNA levels in ventromedial nucleus of the hypothalamus (VMH) (d, f), neuropeptide Y (NPY) and agouti-related 
protein (AgRP) mRNA levels in the arcuate nucleus (ARC) (e, f) and plasma ghrelin levels (G) in fed and fasted growth 
hormone-deficient Lewis rats. Values are expressed as the mean ± SEM. *, **, ***P < 0.05, 0.01 and 0.001, respectively, 
versus fed. 
 
  
Effects of fasting on plasma ghrelin levels in wild-type and GH-deficient Lewis rats 
Plasma ghrelin levels are shown in Figs 2(g) and 3(g). In wild-type Lewis rats fasted for 48 h, 
plasma ghrelin levels increased by 80% compared to the fed group, whereas levels in the dwarf 
group increased by only 40%. 
Effects of chronic central ghrelin treatment on food intake, plasma ghrelin levels and 
hypothalamic lipid metabolism in wild-type Lewis rats 
To shed light on the mechanism involved in fasting induced changes in lipid metabolism in 
normal and GH-deficient rats, we assessed the central effects of ghrelin in both experimental 
models. As expected, chronic i.c.v. ghrelin treatment increased food intake and body weight gain 
(Fig. 4a–c) during the 8-day experimental period in wild-type Lewis rats compared to their saline-
treated controls. As previously reported (19), i.c.v. ghrelin administration elicited an increase in 
plasma ghrelin levels in wild-type Lewis rats (Fig. 4d). To assess the central effect of ghrelin on 
hypothalamic lipid metabolism, protein and activity levels of enzymes involved in the synthesis 
and oxidation of lipids were measured in wild-type Lewis rats (Fig. 5a–c). By contrast to the major 
changes in hypothalamic fatty acid metabolism after acute ghrelin treatment (1, 6, 10, 18), chronic 
i.c.v. ghrelin infusion only increased ACCα and diminished SREBP1c protein levels in the 
hypothalamus (Fig. 5a, b), as well as CPT1 activity (Fig. 5c). Similar to the acute setting (1) central 
chronic ghrelin treatment induced a decrease of FAS mRNA levels in the VMH (Fig. 5d, f). 
Finally, both mRNA levels of NPY and AgRP in ARC were enhanced by ghrelin infusion 
(Fig. 5e, f). 
 
 
 
Figure 4.  Effect of 8-day i.c.v. ghrelin treatment on cumulative daily food intake (a), 
cumulative food intake (b), cumulative body weight gain (c) and plasma ghrelin levels (d) 
in wild-type Lewis rats. Values are expressed as the mean ± SEM. *, **, ***P < 0.05, 
0.01 and 0.001, respectively, versus saline.  
 
 
 
Figure 5  Effect of 8-day i.c.v. ghrelin treatment on hypothalamic protein (a, b) and activity 
levels (c) of lipid metabolism-related enzymes. Fatty acid synthase (FAS) mRNA levels in 
ventromedial nucleus of the hypothalamus (VMH) (d, f) and neuropeptide Y (NPY) and agouti-
related protein (AgRP) mRNA levels in the arcuate nucleus (ARC) (e, f) in wild-type Lewis rats. 
Values are expressed as the mean ± SEM. *, **P < 0.05 and 0.01, respectively, versus saline. 
 
 
  
Effects of chronic central ghrelin treatment on food intake, plasma ghrelin levels and 
hypothalamic lipid metabolism in GH-deficient Lewis rats 
As observed in wild-type Lewis rats, chronic i.c.v. ghrelin treatment increased food intake, 
body weight gain in dwarf rats (Fig. 6a–c) and plasma ghrelin levels (Fig. 6d). By contrast to 
normal rats, ghrelin treatment exerted a profound effect on hypothalamic fatty acid metabolism in 
GH-deficient dwarf rats. Chronic ghrelin administration markedly enhanced protein levels of 
ACCα, AMPKα1, pAMPKα1 CPT1L and SREBP1c (Fig. 7a, b). FAS activity was significantly 
diminished in ghrelin-treated rats (Fig. 7c); however, mRNA levels in VMH did not change in 
those animals (Fig. 7d). In line with the increased food intake in ghrelin-treated rats, NPY and 
AgRP levels in ARC were markedly enhanced in the ARC of dwarf rats after central chronic 
ghrelin treatment (Fig. 7e, f). 
 
 
 
Figure 6.  Effect of 8-day i.c.v. ghrelin treatment on cumulative daily food intake (a), 
cumulative food intake (b), cumulative body weight gain (c) and plasma ghrelin levels 
(d) in growth hormone-deficient Lewis rats. Values are expressed as the mean ± SEM. 
*, **, ***P < 0.05, 0.01 and 0.001, respectively, versus saline. 
  
 
 
 
Figure 7.  Effect of 8-day i.c.v. ghrelin treatment on hypothalamic protein (a, b) and activity 
levels (c) of lipid metabolism-related enzymes. Fatty acid synthase (FAS) mRNA levels in 
ventromedial nucleus of the hypothalamus (VMH) (d, f) and neuropeptide Y (NPY) and agouti-
related protein (AgRP) mRNA levels in the arcuate nucleus (ARC) (e, f) in growth hormone-
deficient Lewis rats. Values are expressed as the mean ± SEM. *, **, ***P < 0.05, 0.01 and 
0.001, respectively, versus saline. 
 
  
Discussion 
The central nervous system (CNS), specifically the hypothalamus, monitors energy needs by 
assessing current energy surplus/deficit and responding by modulating appetite and peripheral 
energy expenditure. Recent data suggest that key regulatory enzymes and intermediates in the fatty 
acid metabolism pathway act as hypothalamic sensors that monitor peripheral signals (such as 
hormones and nutrients/metabolites) to inform about energy status. This in turn acts as a 
mechanism allowing organisms to adjust their food intake and energy expenditure accordingly 
(1,7,8,10,29). Current evidence has also highlighted the key physiological importance of 
hypothalamic fatty acid metabolism in the control of glucose homeostasis and food intake. Thus, 
activation of AMPK in several hypothalamic nuclei, such as the VMH, ARC and PVH, appears to 
play a prominent role in hypoglycaemia-sensing (30), mediating counter-regulatory responses. In 
line with this, central administration of glucose suppresses AMPK activity in the hypothalamus 
(5). α-Lipoic acid, a cofactor of mitochondrial enzymes with antioxidant and anorectic properties, 
also inhibits AMPK activity in the hypothalamus(31). Lastly, i.c.v. administration of citrate elicits 
an anorexigenic response associated with the inhibition of AMPK, activation of ACC and the 
subsequent increase in malonyl-CoA (12). In addition to metabolic regulation, peripheral 
hormones also modulate de novo lipogenesis in the hypothalamus. The evidence for this is that 
anorectic hormones, such as leptin, insulin, GLP-1, ciliary neurotrophic factor and melanocortin 
receptor agonists, including melanotan II, inhibit hypothalamic AMPK (5,6,8,29). On the other 
hand, orexigenic signals, such as cannabinoids, glucocorticoids, thyroid hormones, adiponectin, 
ghrelin and AgRP, activate hypothalamic AMPK, decrease malonyl-CoA levels and increase 
feeding (1,6,9,32–34). Overall, this evidence demonstrates that hypothalamic fatty acid 
metabolism is a bona fide mechanism modulating energy homeostasis at the whole body level. 
 
In the present study, we first studied the effect of GH-deficiency on fatty acid pathway in the 
hypothalamus. The data obtained showed that GH-deficiency induces reductions in both de novo 
lipogenesis and β-oxidation pathways in the hypothalamus. Thus, dwarf rats display reductions in 
FAS mRNA expression both in the VMH and whole hypothalamus, as well as in FAS protein and 
activity and CPT1 activity, probably because of increased malonyl-CoA levels as a result of FAS 
inhibition (1,35,36). Diminished mRNA, protein and activity levels of FAS correlate with reduced 
protein levels of mature SREBP1c, a transcription factor that regulates the expression of several 
genes involved in cellular fatty acid synthesis in the peripheral tissues (37). On the other hand, 
total and pAMPK protein levels were higher in dwarf rats compared to controls. These results 
agree with other studies showing that dwarf rats and GH receptor knockout mice presented total 
and pAMPKα protein levels that were significantly higher compared to their littermate controls in 
peripheral organs, such as the liver (38,39). By contrast, pAMPKα and AMPKα in muscle and 
liver are reduced in mice overexpressing GH compared to their wild type counterparts (40,41). We 
also studied the effect of GH-deficiency on neuropeptide levels in ARC. The selective absence of 
GH, in dwarf rats, results in a decrease in AgRP and NPY mRNA in the ARC. These observations 
are consistent with the results previously described in other studies (23,42) and also with the fact 
that the majority of NPY neurones in the ARC express GH receptor mRNA and the binding of GH 
to its receptor induces the expression of NPY mRNA (43). 
 
Next, we examined the effect of GH-deficiency on fasting-induced effects on hypothalamic 
fatty acid metabolism. As expected, starvation induced a marked, AMPK-dependent inactivation 
of hypothalamic fatty acid synthesis in normal rats, a decrease in CPT1 and FAS activities and a 
specific decrease in FAS mRNA levels in the VMH (1,5). Interestingly, fasting induced a different 
pattern in dwarf rats, which show reduced FAS and CPT1 activities, but unaltered AMPK 
signalling and FAS mRNA expression in the VMH (because it happened after chronic ghrelin 
administration; see below). 
  
Three recent studies have proposed that short-term ghrelin action on the AMPK-malonyl-CPT1 
axis acts as an acute signal, triggering the beginning of feeding after a period of fasting, coincident 
with increased ghrelin levels and increased AgRP and NPY expression in the ARC (1,10,18). 
Although these data provide convincing evidence of short-term ghrelin effects on hypothalamic 
fatty acid metabolism, its chronic effects are less clear. Current evidence has demonstrated that 
central chronic treatment with ghrelin directly increases adiposity by stimulation of the lipogenic 
program in the WAT (19,20). These data suggest that central ghrelin action is of physiological 
relevance in the control of adipocyte metabolism. In this setting, ghrelin, in addition to its 
orexigenic effect, could trigger meal preparation processes in the CNS that stimulate metabolic 
pathways in the WAT to allow more efficient storage of calories. However, no data have been 
reported describing chronic effects of ghrelin on hypothalamic fatty acid metabolism. In the 
present study, we first demonstrate that chronic central ghrelin administration does not induce 
major changes in all the enzymes of hypothalamic fatty acid metabolism in wild-type Lewis rats, 
but specifically decreases FAS mRNA expression in the VMH and hypothalamic CPT1 activity. 
Considering that chronic ghrelin treatment showed a marked orexigenic action and parallel 
changes in AgRP and NPY expression in the ARC, the relevance of these findings is quite 
intriguing. First, they suggest that, in the long-term setting, AMPK-induced changes in 
hypothalamic fatty acid metabolism plays no role in feeding control; indeed, this idea has been 
proposed before, and fatty acid metabolism in the hypothalamus has been suggested as a 
regulatory mechanism designed to preserve energy balance only in situations of starvation (1,10). 
Second, quite opposite to short-term ghrelin action, chronic injection decreased CPT1 activity in 
the hypothalamus, which indicates that, in the long-term setting, ghrelin blocks hypothalamic beta 
oxidation, similar to the results obtained in liver after long-term ghrelin treatment (20). The 
physiological relevance of this action is unclear, although we believe that it could be a 
compensatory mechanism that attempts to ‘brake’ the massive orexigenic signal elicited by central 
hyperghrelinaemia. We based this idea on previous data showing that pharmacological inhibition 
or genetic ablation of hypothalamic CPT1 activity (3,4) or overexpression of MCD (44) induce the 
cytoplasmatic accumulation of fatty acyl-CoA and reduce feeding and body weight. 
 
Besides its role in the regulation of energy balance, ghrelin also regulates the somatotrope axis, 
acting as a potent GH secretagogue in both rodents and humans (13). Although several studies in 
GH-deficient rats have demonstrated that weight gain and adiposity caused by ghrelin are 
independent of its ability to modulate GH secretion (13,16,45), GH receptor deficiency results in 
blunted ghrelin-induced feeding response in mice (24). Thus, we aimed to evaluate whether GH-
deficiency had any effect on ghrelin-induced alterations in hypothalamic fatty acid metabolism. 
We evaluated the effect chronic ghrelin treatment on hypothalamic fatty acid metabolism in dwarf 
rats. The data obtained showed an increase in pAMPK levels in GH-deficient dwarf rats, alongside 
a nonsignificant decrease in CPT1 activity and no change in FAS mRNA and protein expression. 
These results suggest that lack of GH leads to enhanced sensitivity of AMPK signalling to the 
central actions of ghrelin. The molecular underpinnings of this effect are unclear, although it could 
be related to increased hypothalamic GHS-R expression in GH deficiency. Supporting this idea, 
recent studies have demonstrated that, in normal animals, an increased expression of GHS-R 
mRNA was found in several nuclei of hypothalamus and that GHS-R expression was affected by 
GH status, increasing in dwarf rats compared to normal rats from the same strain (23). Increased 
hypothalamic GHS-R expression in GH deficiency could lead to enhanced sensitivity to the central 
actions of ghrelin. On the other hand, wild-type Lewis rats may exhibit desensitisation after 
continuous ghrelin treatment, an effect that was observed after chronic exposure to GHS with 
respect to GH release (16). Whatever the case, the obtained results indicate that chronic ghrelin 
treatment decreased both de novo lipogenesis and beta oxidation in the hypothalamus of dwarf 
rats. Overall, these data suggest that the actions of ghrelin on hypothalamic fatty acid metabolism 
are GH-independent. Considering the important role of GH on peripheral lipid metabolism, the 
physiological relevance of these data is very challenging. In keeping with these observations, we 
have recently demonstrated that central ghrelin effects on adipose and hepatic liver effect do not 
show GH-dependency either (20). 
  
Recent data from our group have demonstrated that the ghrelin-and fasting-induced decrease in 
FAS levels in the VMH is a physiological adaptive mechanism that helps to prevent malonyl-CoA 
from decreasing to deleteriously low levels in the hypothalamus, as a consequence of ghrelin and 
fasting-induced inactivation of ACC by AMPK (1). Because malonyl-CoA plays a critical 
regulatory role in this system by acting both as a substrate for fatty acid biosynthesis and an 
inhibitor of CPT1 (1,46), extremely low levels of malonyl-CoA would compromise neuronal 
viability, by preventing lipid biosynthesis and allowing potentially harmful neuronal fatty acid 
oxidation during fasting, a situation of low energy surplus. Because our data demonstrate that this 
regulatory mechanism is lost in dwarf rats, it is possible that GH-deficiency might elicit altered 
fatty acid fluxes in the hypothalamic neurones that could lead to the accumulation of toxic lipid 
species and lipotoxicity-associated phenomena, such as endoplasmatic-reticulum stress (47,48), 
which could compromise normal hypothalamic function in these animals. Further work will be 
necessary to address these issues (49). 
 
In summary, we demonstrate that both chronic ghrelin and fasting decreased FAS mRNA 
expression in the VMH of normal rats but not dwarf rats, suggesting GH-dependency. In addition, 
the results obtained in the present study provide a clear demonstration that, contrary to short-term 
administration, chronic central ghrelin treatment does not induce major changes in the overall 
fluxes of hypothalamic fatty acid metabolism, and this effect is independent of GH. Overall, these 
results suggest that ghrelin plays a dual time-dependent role in modulating hypothalamic lipid 
metabolism. As a result of this effect, short-term central ghrelin elicits a global AMPK-mediated 
inactivation of fatty acid metabolism pathway, and thus promotes food intake (1,10,16). By 
contrast, in the long-term setting, ghrelin does not induce AMPK-dependent changes in 
hypothalamic fatty acid metabolism, suggesting a lack of role for the ghrelin-AMPK interaction in 
the long-term feeding control. Understanding the molecular mechanism underlying the interplay 
between GH and ghrelin on hypothalamic lipid metabolism will allow new strategies for the 
design and development of suitable drugs for the treatment of GH-deficiency, obesity and its 
comorbidities. 
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